Logo
x

Search category

Subscribe Now

Exclusive License Agreement

NovaRock Signs an Exclusive License Agreement with Flame to Co-Develop and Commercialize NBL-015

NovaRock Signs an Exclusive License Agreement with Flame to Co-Develop and Commercialize NBL-015

  • August 27, 2021
Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115- Proposed Biosimilar to Ustekinumab

Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115- Proposed Biosimilar to Ustekinumab

  • July 23, 2021
Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Technology

Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Tec...

  • July 14, 2021
AstraZeneca Signs an Exclusive License Agreement with F-star Therapeutics for Novel STING Inhibitors

AstraZeneca Signs an Exclusive License Agreement with F-star Therapeutics for Novel STING Inhibitors

  • July 9, 2021
Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

  • March 4, 2021
Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China

Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greate...

  • December 29, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.